ArticlePloS one2025
Comorbidity patterns associated with severe COVID-19 outcomes: A cohort study based on the UK Biobank.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPre-existing comorbidities are linked to increased risk of severe COVID-19, but comprehensive assessments of comorbidity patterns remain limited.
methodsWe used network analysis to identify pre-existing comorbidity modules (i.e., groups of diseases more densely interconnected with each other than with other diseases in the comorbidity network) in a cohort of 420,920 individuals from the UK Biobank who were in England. We defined cases requiring hospitalization or who died of COVID-19 as "severe COVID-19". Logistic regression was used to examine associations between comorbidity modules and severe COVID-19, and a module-based comorbidity index was developed to predict severe COVID-19, compared with existing indices.
resultsComorbidity network analysis identified 190 disease pairs with confirmed comorbidity associations, which were further divided into seven comorbidity modules. Among the 30,914 individuals diagnosed with COVID-19, 3,970 were identified as severe cases (median age of 73.6 years, 58.77% being male). Six of seven identified modules showed statistically significant associations with severe COVID-19, especially modules related to circulatory and respiratory diseases (odds ratio = 1.67 [95% confidence interval 1.54-1.81]) and age-related eye diseases (1.39 [1.27-1.52]). Associations did not differ by sex, age or vaccination status but were generally stronger during the first wave of COVID-19 pandemic (i.e., 31st January-1st October, 2020). Our newly developed module-based comorbidity index showed better performance in predicting severe COVID-19 (AUC = 0.779) compared to the existing Charlson Comorbidity Index (0.714) and the 16-comorbidity index (0.714).
conclusionsOur study demonstrated that pre-existing comorbidity modules, particularly modules related to circulatory and respiratory diseases and age-related eye diseases, were associated with severe COVID-19. Moreover, the module-based comorbidity index provides better prediction of severe COVID-19 than existing prediction indices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.